ClinicalTrials.gg

Program

Lithium Carbonate

Also written as “lithium carbonate”, “Lithium carbonate” and “Lithium Carbonate Capsule”.

Its studies are mostly in Depressive Disorder, Major · Bipolar Disorder, led by 5 companies.

Furthest: phase 3, since Nov 11, 20085 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AstraZeneca10 open or runningphase 3since Nov 11, 2008Nov 11, 2008none ahead
Columbia Northwest Pharmaceuticals10 open or runningphase 2since Mar 18, 2010Mar 18, 2010none ahead
Eli Lilly10 open or runningphase 3since Jun 11, 2007Jun 11, 2007none ahead
JDS Pharmaceuticals10 open or runningphase 3since Jan 11, 2007Jan 11, 2007none ahead
Merck10 open or runningphase 1since Dec 2, 2024Dec 2, 2024none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jan 11, 2007First study: phase 3 study in Bipolar DisorderNew to JDS PharmaceuticalsJDS Pharmaceuticals · NCT00422331 · 206 enrolled · United States
  2. Jun 11, 2007Eli Lilly's first study: phase 3 study in Bipolar DisorderNew to Eli LillyEli Lilly · NCT00485680 · 140 enrolled · China
  3. Nov 11, 2008AstraZeneca's first study: phase 3 study in Depressive Disorder, MajorNew to AstraZenecaAstraZeneca · NCT00789854 · 688 enrolled · Australia, Austria, Belgium and more
  4. Mar 18, 2010Columbia Northwest Pharmaceuticals's first study: phase 2 study in Depressive Disorder, MajorNew to Columbia Northwest PharmaceuticalsColumbia Northwest Pharmaceuticals · NCT01189812 · 80 enrolled · United States
  5. Dec 2, 2024Merck's first study: phase 1 study in HealthyNew to MerckMerck · NCT06719544 · 16 enrolled · United States

TargetBeta

“Inositol-1(or 4)-monophosphatase 1 inhibitor; Glycogen synthase kinase-3 inhibitor”ChEMBL 37, by rule

Studies

All 5 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT06719544Healthy · United States1CompletedMerckJan 27, 202516
NCT01189812Depressive Disorder, Major · United States2CompletedColumbia Northwest PharmaceuticalsJan 201180
NCT00789854Depressive Disorder, Major · Australia, Austria, Belgium and more3CompletedAstraZenecaAug 2009688
NCT00485680Bipolar Disorder · China3CompletedEli Lilly140
NCT00422331Bipolar Disorder · United States3UNKNOWNJDS Pharmaceuticals206

How it is read

Names in the registry

  • “Lithium Carbonate”, 2 entries
  • “lithium carbonate”, 1 entry
  • “Lithium carbonate”, 1 entry
  • “Lithium Carbonate Capsule”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.